Your session is about to expire
← Back to Search
mRNA Vaccine for Respiratory Syncytial Virus
Study Summary
This trial is testing the safety, effectiveness, and immune response of a new vaccine for children aged 2-18 to protect against RSV.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are senior citizens being taken into consideration for this experiment?
"The minimal age for enrollment in this study is 2 and the maximum age accepted is 17."
Who is eligible to partake in this medical experiment?
"To be eligible for the clinical trial, prospective participants must have respiratory syncytial virus and fall within the 2 to 17 age bracket. In total, 340 individuals will take part in this study."
Is it permissible for Cohort 1 (2 to <5 Years of Age) to partake in this FDA approved trial?
"Our evaluation of Cohort 1 (2 to <5 Years of Age) safety is a 2, as there has only been prior data demonstrating its security but not any efficacy."
How many distinct locations are responsible for administering this research?
"The trial is hosted in 21 different medical centres around the country, with Med-Care Research located in Miami and Accel Research Sites - Nona Pediatric Center stationed in Orlando being two of them. Seminole's own Accel Clinical also plays host to this research project, alongside 18 other sites."
Is there an opportunity to join the experiment at this juncture?
"This trial, which was initially posted on October 23rd 2023 and last updated on the 18th of October in the same year, is not actively seeking patients. Nevertheless, 105 other studies are recruiting new participants right now."
Share this study with friends
Copy Link
Messenger